Precision BioSciences (DTIL) shares were up nearly 27% in recent trading Friday, a day after its partner iEcure reported positive data on its in vivo gene insertion program and upgrade Friday from BMO Capital.
BMO Capital upgraded the company's stock to outperform from market perform, with a $34 price target.
iEcure reported positive data from the phase 1/2 study in the first patient treated with ECUR-506 for neonatal onset OTC deficiency, a hereditary metabolic disorder.
The treatment was well-tolerated overall, with only asymptomatic transaminitis noted at four weeks, which was managed with immunosuppressive therapy and resolved within another four weeks, it added.
Price: 5.70, Change: +1.20, Percent Change: +26.67
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。